Literature DB >> 18509087

Retrovirally induced CTL degranulation mediated by IL-15 expression and infection of mononuclear phagocytes in patients with HTLV-I-associated neurologic disease.

Yoshimi Enose-Akahata1, Unsong Oh, Christian Grant, Steven Jacobson.   

Abstract

CD8(+) T cells contribute to central nervous system inflammation in human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). We analyzed CD8(+) T-cell dysfunction (degranulation and IFN-gamma production) and have demonstrated that CD8(+) T cells of patients with HAM/TSP (HAM/TSP patients) spontaneously degranulate and express IFN-gamma in ex vivo unstimulated culture. CD8(+) T cells of HTLV-I asymptomatic carriers and healthy donors did not. Spontaneous degranulation was detected in Tax11-19/HLA-A*201 tetramer(+) cells, but not in CMV pp65 tetramer(+) cells. Interestingly, degranulation and IFN-gamma production in CD8(+) T cells was induced by coculture with autologous CD14(+) cells, but not CD4(+) T cells, of HAM/TSP patients, which correlated with proviral DNA load in CD14(+) cells of infected patients. Moreover, the expression of IL-15, which induced degranulation and IFN-gamma production in infected patients, was enhanced on surface of CD14(+) cells in HAM/TSP patients. Blockade of MHC class I and IL-15 confirmed these results. Thus, CD8(+) T-cell dysregulation was mediated by both virus infection and enhanced IL-15 on CD14(+) cells in HAM/TSP patients. Despite lower viral expression than in CD4(+) T cells, HTLV-I-infected or -activated CD14(+) cells may be a heretofore important but under recognized reservoir particularly in HAM/TSP patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509087      PMCID: PMC2532810          DOI: 10.1182/blood-2008-02-138529

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

1.  The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration.

Authors:  Michael R Betts; David A Price; Jason M Brenchley; Karin Loré; F Javier Guenaga; Anna Smed-Sorensen; David R Ambrozak; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling.

Authors:  Graham G Neely; Slava Epelman; Ling Ling Ma; Pina Colarusso; Christopher J Howlett; Ernest K Amankwah; Amanda C McIntyre; Stephen M Robbins; Christopher H Mody
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

3.  Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold.

Authors:  Mustapha Faroudi; Clemens Utzny; Mariolina Salio; Vincenzo Cerundolo; Martine Guiraud; Sabina Müller; Salvatore Valitutti
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-10       Impact factor: 11.205

4.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

5.  Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I.

Authors:  M Siekevitz; M B Feinberg; N Holbrook; F Wong-Staal; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

6.  Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I.

Authors:  S L Cross; M B Feinberg; J B Wolf; N J Holbrook; F Wong-Staal; W J Leonard
Journal:  Cell       Date:  1987-04-10       Impact factor: 41.582

7.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

8.  Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Amir H Sabouri; Mineki Saito; Alun L Lloyd; Alison M Vine; Aviva W Witkover; Yoshitaka Furukawa; Shuji Izumo; Kimiyoshi Arimura; Sara E F Marshall; Koichiro Usuku; Charles R M Bangham; Mitsuhiro Osame
Journal:  J Infect Dis       Date:  2004-08-31       Impact factor: 5.226

9.  Reverse signaling through membrane-bound interleukin-15.

Authors:  Vadim Budagian; Elena Bulanova; Zane Orinska; Thomas Pohl; Ernest C Borden; Robert Silverman; Silvia Bulfone-Paus
Journal:  J Biol Chem       Date:  2004-07-28       Impact factor: 5.157

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  23 in total

1.  Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.

Authors:  Jing Chen; Mike Petrus; Bonita R Bryant; Vinh Phuc Nguyen; Carolyn K Goldman; Richard Bamford; John C Morris; John E Janik; Thomas A Waldmann
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

Review 2.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

3.  The NK cell as a new player in the pathogenesis of HTLV-I associated neurologic disease.

Authors:  Steven Jacobson
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

Review 4.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

Review 5.  Functions of IL-15 in anti-viral immunity: multiplicity and variety.

Authors:  Katherine C Verbist; Kimberly D Klonowski
Journal:  Cytokine       Date:  2012-06-15       Impact factor: 3.861

6.  Dynamic acquisition of HTLV-1 tax protein by mononuclear phagocytes: Role in neurologic disease.

Authors:  Eiji Matsuura; Yoshimi Enose-Akahata; Karen Yao; Unsong Oh; Yuetsu Tanaka; Hiroshi Takashima; Steven Jacobson
Journal:  J Neuroimmunol       Date:  2016-10-03       Impact factor: 3.478

7.  Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Raya Massoud; Yoshimi Enose-Akahata; Yutaka Tagaya; Nazli Azimi; Asjad Basheer; Steven Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

8.  High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease.

Authors:  Yoshimi Enose-Akahata; Eiji Matsuura; Unsong Oh; Steven Jacobson
Journal:  PLoS Pathog       Date:  2009-12-04       Impact factor: 6.823

9.  Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans.

Authors:  Maria Fernanda de Castro-Amarante; Cynthia A Pise-Masison; Katherine McKinnon; Robyn Washington Parks; Veronica Galli; Maria Omsland; Vibeke Andresen; Raya Massoud; Giovanna Brunetto; Breanna Caruso; David Venzon; Steven Jacobson; Genoveffa Franchini
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

10.  Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.

Authors:  Yoshihisa Yamano; Natsumi Araya; Tomoo Sato; Atae Utsunomiya; Kazuko Azakami; Daisuke Hasegawa; Toshihiko Izumi; Hidetoshi Fujita; Satoko Aratani; Naoko Yagishita; Ryoji Fujii; Kusuki Nishioka; Steven Jacobson; Toshihiro Nakajima
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.